Lebrec D, Moreau R, Cailmail S, Sogni P, Oberti F, Hadengue A
Unité de Recherches de Physiopathologie Hépatique (INSERM U-24), Hôpital Beaujon, Clichy, France.
J Hepatol. 1993 Jan;17(1):102-7. doi: 10.1016/s0168-8278(05)80529-x.
Terlipressin is used in patients with variceal bleeding but its effects in patients receiving beta-adrenergic antagonists are unknown. In this study, the hemodynamic effects of terlipressin were evaluated in conscious portal hypertensive rats which had previously received a single dose of propranolol. Moreover, oxygen content and acid-base status were studied. In portal vein stenosed and cirrhotic rats, the addition of terlipressin (0.05 mg/kg) to propranolol (0.4 mg/kg) produced a decrease in portal pressure of 34% and 17%, respectively, and in portal tributary blood flow of 46% and 42%, respectively. In cirrhotic rats, however, the decrease in portal pressure was not significantly different when propranolol was combined with terlipressin than when propranolol was administered alone. Cardiac index also further decreased after terlipressin administration. In both groups of rats, these values were similar to those observed after terlipressin alone. In portal vein stenosed rats but not in cirrhotic rats, arterial pH was significantly lower following the combination of propranolol plus terlipressin than following saline, propranolol or terlipressin alone. In conclusion, terlipressin further reduces both portal pressure and cardiac index in rats with portal hypertension receiving beta-blockers. In portal vein stenosed rats but not in cirrhotic rats, the addition of terlipressin to propranolol induces acidemia. This study suggests that terlipressin might further reduce portal pressure in patients with portal hypertension treated with beta-blockers.
特利加压素用于治疗静脉曲张出血患者,但其对接受β-肾上腺素能拮抗剂治疗的患者的影响尚不清楚。在本研究中,对预先接受单剂量普萘洛尔治疗的清醒门静脉高压大鼠评估了特利加压素的血流动力学效应。此外,还研究了氧含量和酸碱状态。在门静脉狭窄和肝硬化大鼠中,在普萘洛尔(0.4mg/kg)基础上加用特利加压素(0.05mg/kg)后,门静脉压力分别降低了34%和17%,门静脉分支血流量分别降低了46%和42%。然而,在肝硬化大鼠中,普萘洛尔与特利加压素联合使用时门静脉压力的降低与单独使用普萘洛尔时相比无显著差异。特利加压素给药后心脏指数也进一步降低。在两组大鼠中,这些值与单独使用特利加压素后观察到的值相似。在门静脉狭窄大鼠而非肝硬化大鼠中,普萘洛尔加特利加压素联合用药后的动脉pH值显著低于生理盐水、普萘洛尔或特利加压素单独用药后的pH值。总之,特利加压素可进一步降低接受β受体阻滞剂治疗的门静脉高压大鼠的门静脉压力和心脏指数。在门静脉狭窄大鼠而非肝硬化大鼠中,普萘洛尔加用特利加压素会导致酸血症。本研究表明,特利加压素可能会进一步降低接受β受体阻滞剂治疗的门静脉高压患者的门静脉压力。